NCT02333188 - Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Adenocarcinoma of Unknown PrimaryAdult CholangiocarcinomaGallbladder CarcinomaGastric AdenocarcinomaMalignant Gastrointestinal NeoplasmMetastatic Pancreatic AdenocarcinomaPancreatic AdenocarcinomaStage III Ampulla of Vater CancerStage III Pancreatic CancerStage IIIA Gallbladder CancerStage IIIA Gastric CancerStage IIIB Gallbladder CancerStage IIIB Gastric CancerStage IV Ampulla of Vater CancerStage IV Gallbladder CancerStage IV Gastric CancerStage IV Pancreatic Cancer

Interventions

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Fluorouracil

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

46202

Indiana University Medical Center, Indianapolis

46845

Fort Wayne Medical Oncology/Hematology, Fort Wayne

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

60201

NorthShore University Health System, Evanston

60426

Ingalls Memorial Hospital, Harvey

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

98101

Virginia Mason, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER